It does link to the recent Yang manuscript. CytoDyn's new PR team seems to be getting the leronlimab story out a little better now.
This is good press even if not in depth because the more people hear about it, the more people will ask questions about it and the more people will look into the stock.
And, the more people that know about it, the harder it is for a governmental agency to bury it.
NewsMax is to the right of FoxNews, but this is all good because conservatives do have money to spend on stocks.